Next-generation therapeutic vaccines company also welcomes industry veteran Eric Halioua to board, as executive chairman. Lead candidate ErVac01 is a cancer vaccine targeting novel tumor antigens derived from human endogenous retroviruses. Lyon, France, January 21, 2026 – ErVimmune, a biotechnology company … Read More